Compare RNA & SOCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNA | SOCA |
|---|---|---|
| Founded | 2025 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.5M | 242.7M |
| IPO Year | 2025 | 2025 |
| Metric | RNA | SOCA |
|---|---|---|
| Price | $7.94 | $10.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 419.4K | 60.9K |
| Earning Date | 08-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | N/A |
| Revenue This Year | $84.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $172.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.63 | $10.00 |
| 52 Week High | $73.06 | $10.36 |
| Indicator | RNA | SOCA |
|---|---|---|
| Relative Strength Index (RSI) | 24.73 | 64.65 |
| Support Level | N/A | $10.28 |
| Resistance Level | $14.05 | N/A |
| Average True Range (ATR) | 0.46 | 0.00 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 12.10 | 100.00 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Solarius Capital Acquisition Corp is a blank check company.